SHZ Healthcare Medical - Devices 300318.SZ

Beijing Bohui Innovation Biotechnology Group Co., Ltd.

$ 4.45 -1.11 %

Beijing Bohui Innovation Biotechnology Group Co., Ltd. is a Chinese enterprise that manages the full spectrum of diagnostic product operations, from initial research and development through manufacturing, sales, and post-sale support. Their offerings include a variety of diagnostic tools such as the GenPlex microfluidic automated system for nucleic acid detection, immunofluorescence detection solutions, and products for analyzing human trace elements. Additionally, the company provides advanced chemical analysis instrumentation, featuring atomic fluorescence spectrometers, photometers, mass spectrometers, chip ion sources, microfluidic flow chemical analysis systems, and ICP spectroscopy equipment, along with vital consumables for life sciences. Founded in 2001, the company is headquartered in Beijing, China. It adopted its current name, Beijing Bohui Innovation Biotechnology Group Co., Ltd., in August 2021, having previously been known as Beijing Bohui Innovation Biotechnology Co., Ltd.

CEO: Zhiwei Shen - https://www.bohui-tech.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ -13.03

Loading data...

300318.SZ vs S&P500

Loading data...

No data available.

Quick ratio

0.19

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

-37.08

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.12

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-7.22 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-3.11 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

4.39

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.73

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-0.37

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

-21.15 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
1 indicates worrying financial health
Altman score
0.95 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.09 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.21 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.